Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477152 | 1.00 | MCHR1 (0.40) | MCHR1CA12CA1CA2CA7 | |
| Hydrochloric Acid SCHEMBL22721693 | 0.76 | RAB9A (0.40) | MCHR1PPARAPPARGALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL22721692 | 0.76 | RAB9A (0.40) | MCHR1PPARAPPARGALDH1A1HSD17B10 | |
| SCHEMBL15971390 | 0.75 | CA12 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL6469761 | 0.75 | ALDH1A1 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL4475569 | 0.74 | CA12 (0.40) | MCHR1CA12CA1CA2CA7 | |
| SCHEMBL4475575 | 0.74 | CA12 (0.40) | MCHR1CA12CA1CA2CA7 | |
| SCHEMBL4475571 | 0.74 | CA12 (0.40) | MCHR1CA12CA1CA2CA7 | |
| SCHEMBL284305 | 0.73 | CA12 (0.74) | CA12CA1CA2CA7CA9 | |
| SCHEMBL10795237 | 0.73 | CYP1A2 (0.49) | MCHR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| EP-1989198-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
| CN-101044137-A | 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2007-09-26 | — | — | CN | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
| WO-2007096351-A1 | 2,4-DIAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT AND/OR PREVENTION OF CANCER, INFECTIONS, INFLAMMATORY AND AUTOIMMUNE DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-30 | — | — | WO | disclosed |
| EP-1781640-A1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006021544-A1 | 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | MCHR1 4720/4885CA12 4884/4885CA1 4848/4885 |
| US-20110086842-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | MCHR1 4720/4885CA12 4884/4885CA1 4848/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | MCHR1 4720/4885CA12 4884/4885CA1 4848/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | MCHR1 283/4885CA12 3528/4885CA1 4137/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | MCHR1 4720/4885CA12 4884/4885CA1 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.